Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora

Regulatory Toxicology and Pharmacology

Volumn 29, Issue 3, 1999, Pages 238-261

  Cerniglia, Carl E ^a   Kotarski, Susan ^b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; DIHYDROSTREPTOMYCIN; DRUG RESIDUE; ENROFLOXACIN; NEOMYCIN; NOVOBIOCIN; STREPTOMYCIN; TETRACYCLINE; TILMICOSIN; VETERINARY DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; EXPERIMENTAL ANIMAL; FECES CULTURE; FOOD AND DRUG ADMINISTRATION; FOOD CONTAMINATION; FOOD SAFETY; GRAM NEGATIVE BACTERIUM; HUMAN; INTESTINE FLORA; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VETERINARY MEDICINE; VOLUNTEER;

EID: 0032996673     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1999.1300     Document Type: Article

References (131)

1. Anonymous (1987). Insert labeling, Albamycin brand of novobiocin sodium capsules, The Upjohn Co. (Kalamazoo, MI 49001, March 1987).
2. Andremont, A., Raibaud, P., and Tancrede, C. (1983). Effect of erythromycin on microbial antagonisms: A study in gnotobiotic mice associated with a human fecal flora. J. Infect. Dis. 148, 579-587.
3. Aschbacher, P. W., and Feil, V. J. (1994). Neomycin metabolism in calves. J. Animal Sci. 72, 683-689.
4. Bartlett, J. G. (1981). Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea or colitis. Johns Hopkins Med. J. 149, 6-9.
5. Bates, J., Jordens, J. Z., and Griffiths, D. T. (1994). Farm animals as a putative reservoir for vancomycin-resistant enterococcal infections in man. J. Antimicrob. Chemother. 34, 507-516.
6. Boisseau, J. (1993). Basis for the evaluation of the microbiological risks due to veterinary residues in food. Vet. Microbiol. 35, 187-192.
7. Brady, M. S., and Katz, S. E. (1988). Method to determine effect of antibiotics at residue levels on r-factor transfer. J. Assoc. Off. Anal. Chem. 71, 299-301.
8. Brady, M. S., White, N., and Katz, S. E. (1993). Resistance development potential of antibiotic/antimicrobial residue levels designated as "safe levels." J. Food Prof. 56, 229-233.
9. Breen, K. J., Bryant, R. E., and Levinson, J. D. (1972). Neomycin absorption in man. Ann. Int. Med. 76, 211-218.
10. Carman, R. J., Van Tassell, R. L., and Wilkins, T. D. (1993). The normal intestinal microflora: ecology, variability and stability. J. Vet. Human Toxicol. 35(Suppl.), 11-14.
11. Chadwick, R. W., George, S. E., and Claxton, L. R. (1992). Role of gastrointestinal mucosa and microflora in the bioactivation of dietary and environmental mutagens or carcinogens. Drug Metab. Rev. 24, 425-492.
12. Committee for Veterinary Medicine (CVM). (1994). Guideline for establishing a withdrawal period. In General Principles for Evaluating the Safety of Compounds Used in Food-producing Animals, Guideline VI, part A. U.S. Food and Drug Administration of the Department of Health and Health Human Services.
13. Committee for Veterinary Medicinal Products (CVMP). (1995). Safety evaluation of antimicrobial substances regarding the effects on human gut flora. Committee for Veterinary Medicinal Products Working Party on the Safety of Residues, Brussels, Belgium. [Guideline Document No. III/5619/94-EN]
14. Committee for Veterinary Medicinal Products (CVMP). (1997). Note for guidance: Approach towards harmonisation of withdrawal periods [EMEA/CVMP 036: 95]
15. Corpet, D. E. (1987). Antibiotic residues and drug resistance in human intestinal flora. Antimicrob. Agents Chemother. 31, 587-593.
16. Corpet, D. E. (1992). Current status of models for testing antibiotic residues. Vet. Human Toxicol. 35(Suppl. 1), 37-46.
17. Corpet, D. E. (1993). An evaluation of methods to assess the effect of antimicrobial residues on the human gut flora. Vet. Microbiol. 35, 199-212.
18. Corpet, D. E., Lumeau, S., and Corpet, F. (1989). Minimum antibiotic levels for selecting a resistance plasmid in a gnotobiotic animal model. Antimicrob. Agents Chemother. 33, 535-540.
19. Coulson, C. J., and Smith, V. J. (1980). Correlation of hydrophobicity with protein binding for clorobiocin analogs. J. Pharm. Sci. 69, 789-801.
20. Craig, W. A., and Suh, B. (1986). Protein binding and the antimicrobial effects: methods for the determination of protein binding. In Antibiotics in Laboratory Medicine (V. Lorian, Ed.), pp. 477-514. Williams & Wilkins, Baltimore, MD.
21. Cummings, J. H., Banwell, J. G., Segal, I., Coleman, N., Englyst, H. N., and MacFarlane, G. T. (1990). The amount and composition of large bowel contents in man. Gastroenterology 98, A408.
22. Cummings, J. H., Jenkins, D. J. A., and Wiggins, H. (1976). Measurement of the mean transit time of dietary residue through the human gut. Gut 17, 210-218.
23. Cunliffe, W. J., and Cotterill, J. A. (1973). Clindamycin as an alternative to tetracycline in severe acne vulgaris. Practitioner 210, 698-700.
24. Cunliffe, W. J., Cotterill, J. A., and Williamson, B. (1972). The effect of clindamycin in acne - A clinical and laboratory investigation. Br. J. Dermatol. 87, 37-41.
25. DeHaan, M., and Pfeifer, T. (1975). In vitro susceptibility of anaerobic isolates with reference to selection of therapeutic agents. Infect. Dis. Rev. 3, 37-57.
26. Donnelly, J. P., Voss, A., Witte, W., and Murray, B. E. (1996). Does the use in animals of antimicrobial agents, including glycopeptide antibiotics, influence the efficacy of antimicrobial therapy in humans? J. Antimicrob. Chemother. 37, 389-392. [letter]
27. Dornbusch, K., Nord, C.-E., and Dahlback, A. (1975). Antibiotic susceptibility of Clostridium species isolated from human infections. Scand. J. Infect. Dis. 7, 127-134.
28. Dowling, H. F. (1995). Tetracycline. Antibiotics Monogr. 3, 1-62.
29. Drasar, B. S., and Duerden, B. I. (1991). Anaerobes in the normal flora of man. In Anaerobes in Human Disease (B. I. Duerden and B. S. Drasar, Eds.), pp. 162-179. Wiley-Liss, New York.
30. Edlund, C., Lindqvist, L., and Nord, C. E. (1988). Norfloxacin binds to human fecal material. Antimicrob. Agents Chemother. 32, 1869-1874.
31. Egger, R., and Lebek, G. (1985). Selection of R-plasmid harbouring E. coli by subinhibitory concentrations of antibiotics. Zentralbl. Bakt. Hyg. A260, 361-368.
32. El Oufir, L., Flouirié, B., Bruley des Varannes, S., Barry, J. L., Cloarec, D., Bornet, F., and Galmiche, J.-P. (1996). Relations between transit time, fermentation products and hydrogen consuming flora in healthy humans. Gut 38, 870-877.
33. Endtz, H. P. (1991). Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother. 24, 199-208.
34. Fass, R. J. (1980). Lincomycin and clindamycin. In Antimicrobial Therapy, pp. 97-114. Saunders, Philadelphia.
35. Fekety, R., Silva, J., Toshniwal, R., Allo, M., Armstrong, J., Browne, R., Ebright, J., and Rifkin, G. (1979). Antibiotic-associated colitis: Effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev. Infect. Dis. 1, 386-397.
36. Fenton, S. (1974). Pseudomembranous colitis associated with antibiotic therapy - An emerging entity. CVM J. 111, 1110-1114.
37. Fernandez, A. H. (1998). Current views in the USA for microbiologically active compounds. Proceedings of the Conference for Global Developments in Risk Assessment of Residues of Veterinary Drugs, Brussels, Belgium.
38. Finegold, S. M., Mathisen, G. E., and George, W. L. (1983). Changes in human intestinal flora related to the administration of antimicrobial agents. In Human Intestinal Flora in Health and Disease (D. J. Hentges, Ed.), pp. 355-446. Academic Press, San Diego.
39. Finegold, S. M., Posnick, D. J., Miller, L. G., and Hewitt, W. L. (1965). The effect of various antibacterial compounds on the normal human fecal flora. Ernaehrungsforschung 10, 316-341.
40. Fink-Gremmels, J., and van Miert, A. S. J. P. A. M. (1994). Veterinary drugs: Disposition, biotransformation and risk evaluation. Analyst 119, 2521-2528.
41. Gilbert, D. N. (1994). Aspects of the safety profile of oral antibacterial agents. Infect. Dis. Clin. Pract. 3, 236-247.
42. Gorbach, S. L. (1995). Perturbation of intestinal microflora. Vet. Human Toxicol. 35, 15-23.
43. Hazenberg, M. P., Baker, M., and Verschoor-Burggraaf, A. (1981). Effects of the human intestinal microflora on germ-free mice. J. Appl. Bacteriol. 50, 95-106.
44. Hazenberg, M. P., Pennock-Schroder, A. M., Van den Boom, M., and Van de Merwe, J. P. (1984). Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human faeces. J. Hyg. 93, 27-34.
45. Hazenberg, M. P., van de Boom, M., Bakker, M., and van de Merwe, J. P. (1983). Binding to faeces and influence on human anaerobes of antimicrobial agents used for selective decontamination. Antonie van Leeuwenhoek 49, 111-117.
46. Heimdahl, A., and Nord, C. E. (1982). Effect of erythromycin and clindamycin on the indigenous human anaerobic flora and new colonization of the gastrointestinal tract. Eur. J. Clin. Microbiol. 1, 38-48.
47. Hewitt, W. L. L., Finegold, W. M., and Sutter, V. L. (1956). Incidence of side effects and changes in fecal microflora following administration of tetracycline and tetracycline-nystatin. In Antibiotics Annual, pp. 856-861.
48. Hirayama, K., Itoh, K., Takahashi, E., and Mitsuoka, T. (1995). Comparison of composition of fecal microbiota and metabolism of fecal bacteria among "human-flora-associated" mice inoculated with faeces from six different human donors. Microb. Ecol. Health Dis. 8, 199-211.
49. Hirayama, K., Kawamura, S., and Mitsuoka, T. (1991). Development and stability of human fecal flora in the intestine of ex-germ-free mice. Microb. Ecol. Health Dis. 4, 95-99.
50. Hirsh, D. C., Burton, G. C., Blenden, D. C., and Tsutakawa, R. (1974). The effect of tetracycline upon establishment of Escherichia coli of bovine origin in the enteric tract of man. J. Appl. Bacteriol. 37, 327-333.
51. Hirshhorn, L. R., Trnka, Y., Onderdonk, A., Lee, M-L. T., and Platt, R. (1994). Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J. Infect. Dis. 169, 127-133.
52. Holdeman, L. V., Cato, E. P., and Moore, W. E. C. (1977). Anaerobe Laboratory Manual, 4th ed., p. 156. Anaerobe Laboratory, Virginia Polytechnic Inst. and State Univ., Blacksburg, VA.
53. Høverstad, T., and Bjørneklett, A. (1984). Short-chain fatty acids and bowel function in man. Scand. J. Gastroenterol. 19, 1059-1065.
54. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1991a). Evalution of certain veterinary drug residues in food: Thirty-eighth report of the Joint FAO/WHO Expert Committee on Food Additives. In WHO Technical Report Series, 815, Annex 5. WHO, Geneva.
55. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1991b). Toxicological evaluation on certain veterinary drug residues in food: Thirty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, No. 27. WHO, Geneva.
56. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1995). Toxicological evaluation of certain veterinary drug residues in food. WHO Food Additives Series, No. 34. WHO, Geneva.
57. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1996a). Evaluation of certain veterinary drug residues in food: Forty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, No. 36. WHO, Geneva.
58. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1996b). Toxicological evaluation of certain veterinary drug residues in food: Monograph Prepared by the Forty-seventh Meeting of the Joint FAO/WHO Expert Committee on Food Additives. WHO Food Additives Series, No. 38. WHO, Geneva.
59. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1997). Toxicological evaluation of certain veterinary drug residues in food: Forty-eighth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, No. 39. WHO, Geneva.
60. Joint FAO/WHO Expert Committee on Food Additives (JECFA) (1998). Evaluation of certain veterinary drug residues in food: Forty-seventh report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, No. 876. WHO, Geneva.
61. Johnson, A. P., Burns, L., Woodford, N., Threlfall, E. J., Naidoo, J., Cooke, E. M., and George, R. C. (1994). Gentamicin resistance in clinical isolates of Escherichia coli encoded by genes of veterinary origin. J. Med. Microbiol. 40, 221-226.
62. Kelly, C. P., Pothoulakis, C., and LaMont, J. T. (1994). Clostridium colitis. N. Engl. J. Med. 330, 257-262.
63. Klempner, M. S., and Styrt, B. (1988). Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. J. Am. Med. Assoc. 260, 2682-2685.
64. th European Association for Veterinary Pharmacology and Toxicology International Congress, Madrid, Spain.
65. Kunin, C. M., Chalmers, T. C., and Leevy, C. M. (1960). Absorption of orally administered neomycin and kanamycin. N. Engl. J. Med. 262, 380-385.
66. Langendijk, P. S., Schut, F., Jansen, G. J., Raangs, G. C., Kamphuis, G. R., Wilkinson, M. H., and Welling, G. W. (1995). Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus specific 16S rRNA-targeted probes and its application in fecal samples. Appl. Environ. Microbiol. 61, 3069-3075.
67. Levy, S. B., Marshall, B., Schluederberg, S., Rowse, D., and Davis, J. (1988). High frequency of antimicrobial resistance in human fecal flora. Antimicrob. Agents Chemother. 32, 1801-1806.
68. Limson, B. M., and Romansky, M. J. (1956). Novobiocin, a new antibiotic: Laboratory and clinical evaluation of thirty patients with bacterial pneumonia. Antibiotic Med. II, 277-281.
69. Lubash, G., Van Der Meulen, J., Bernsten, C. Jr., and Tompsett, R. (1956). Novobiocin: A laboratory investigation. Antibiotic Med. II, 233-240.
70. Lusk, R. H., Fekety, R., Silva, J., Browne, R. A., Ringler, D. H., and Abrams, G. D. (1978). Clindamycin-induced enterocolitis in hamsters. J. Infect. Dis. 137, 464-475.
71. Lyerly, D. M., Krivan, H. C., and Wilkins, T. D. (1988). Clostridium difficile: Its disease and toxins. Clin. Microbiol. Rev. 1, 1-18.
72. Mallett, A. K., Bearne, C. A., Rowland, I. R., Farthing, M. J., Cole, C. B., and Fuller, R. (1987). The use of rats associated with human fecal flora as a model for studying the effects of diet on the human microflora. J. Appl. Bacteriol. 63, 39-45.
73. McConville, M. L., Dijkstra, J. W., Stamm, J. M., van Saene, J. J., and Nouws, J. F. (1995). Effects of sarafloxacin hydrochloride on human enteric bacteria under simulated human gut conditions. Vet. Q. 17, 1-5.
74. McHardy, G., McHardy, R., Ward, S., and Cradic, H. (1956). A clinical evaluation of novobiocin in amebiasis. Antibiotic Med. II, 230-232.
75. Midtvedt, T. (1986). Effects of antimicrobial agents upon the functional part of the intestinal flora. Scand. J. Infect. Dis. Suppl. 49, 85-88.
76. Midtvedt, T. (1990). The influence of quinolones on the faecal flora. Scand. J. Infect. Dis. Suppl. 68, 14-18.
77. Milberg, M. B., Schwartz, R. D., and Wilverstein, J. N. (1956). Novobiocin: A preliminary report of therapeutic efficacy. Antibiotic Med. II, 286-289.
78. Moore, W. E., and Holdeman, L. V. (1974). Human fecal flora: The normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 27, 961-979.
79. Moore, W. E. C., and Moore, L. H. (1995). Intestinal floras of populations that have a high risk of colon cancer. Appl. Environ. Microbiol. 61, 3202-3207.
80. Morton, R. F., Prigot, A., and Maynard, A. de L. (1956). The clinical evaluation of novobiocin, a new antibiotic. Antibiotic Med. II, 282-285.
81. Mullins, J. F., and Wilson, C. J. (1956). Novobiocin treatment of pyodermas. Antibiotic Med. II, 201-204.
82. National Committee for Clinical Laboratory Standards (1993). Methods for Antimicrobial Susceptibility Testing, 3rd ed., p. 23. Approved Standard. NCCLS, Villanova, PA.
83. National Council for Clinical Laboratory Standards (1994). Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, p. 45. Proposed Standard. NCCLS, Villanova, PA.
84. Nielsen, E. M., and Schlundt, J. (1992). Use of norfloxacin to study colonization ability of Escherichia coli in in vivo and in vitro models of the porcine gut. Antimicrob. Agents Chemother. 36, 401-407.
85. Nord, C. E. (1988). Effect of new quinolones on the human gastrointestinal microflora. Rev. Infect. Dis. 10(Suppl. 1), S193-S196.
86. Nord, C. E. (1993). The effect of antimicrobial agents on the ecology of the human intestinal microflora. Vet. Microbiol. 35, 193-197.
87. Nord, C. E., Kager, L., and Heimdahl, A. (1984). Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am. J. Med. 76, 99-106.
88. Nord, C. E., and Edlund, C. (1991). Ecological effects of antimicrobial agents on the human intestinal flora. Microb. Ecol. Health Dis. 4, 193-207.
89. Nouws, J. F. M., Kuiper, H., van Klingeren, B., and Kruyswijk, P. G. (1994). Establishment of a microbiologically acceptable daily intake of antimicrobial drug residues. Vet. Q. 16, 152-156.
90. Pecquet, S., Andremont, A., and Tancrede, C. (1986). Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob. Agents Chemother. 29, 1047-1052.
91. Piddock, L. J. V. (1996). Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy? J. Antimicrob. Chemother. 38, 1-3.
92. Pines, A., Raafat, H., Plucinski, K., Greenifield, J. S. B., and Solari, M. (1969). A comparison of erythromycin, novobiocin, tetracycline and a novobiocin-tetracycline combination in purulent exacerbations of chronic bronchitis. Br. J. Dis. Chest. 63, 206-214.
93. Poth, E. J., Fromm, S. M., Wise, R. I., and Hsiang, C. M. (1950). Neomycin, a new intestinal antiseptic. Texas Rep. Biol. Med. 8, 353-360.
94. Raibaud, P., Ducluzeau, R., Dubos, F., Hudault, S., Bewa, H., and Muller, M. C. (1980). Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. Am. J. Clin. Nutr. 33, 2440-2447.
95. Rao, S. S., Edwards, C. A., Austen, C. J., Bruce, C., and Read, N. W. (1988). Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 94, 928-932.
96. Read, N. W., Miles, C. A., Fisher, D., Holgate, A. M., Kime, N. D., Mitchell, M. A., Reeve, A. M., Roche, T. B., and Walker, M. (1980). Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea. Gastroenterology 79, 1276-1282.
97. Reeves, D. S. (1986). The effect of quinolone antibacterials on the gastrointestinal flora compared with that of other antibacterials. J. Antimicrob. Chemother. 18(Suppl. D), 89-102.
98. Reimer, L. G., Stratton, C. W., and Reller, B. (1981). Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob. Agents Chemother. 19, 1050-1055.
99. Riley, H. D. Jr. (1970). Vancomycin and novobiocin. Med. Clin. N. Am. 54, 1277-1289.
100. Rollins, L. D, Gaines, S. A, Pocurull, D. W., and Mercer, H. D. (1975). Animal model for determining the no-effect level of an antimicrobial drug on drug resistance in the lactose-fermenting enteric flora. Antimicrob. Ag. Chemother. 7, 661-665.
101. Rumney, C. J., and Rowland, I. R. (1992). In vivo and in vitro models of the human colonic flora. Crit. Rev. Food Sci. Nutr. 31, 299-331.
102. Rumney, C. J., and Rowland, I. R. (1995). Microbiological endpoint testing for veterinary antimicrobials - Setting MRLs. Food Chem. Toxicol. 33, 331-333.
103. Rumney, C. J., Coutts, J. T., Smith, J. S., and Rowland, I. R. (1998). Microbiological end-point determination of antibiotics. Microb. Ecol. Health Dis. 10, 3-11.
104. Scheppach, W., Fabian, C., Sachas, M., and Kasper, H. (1988). The effect of starch malabsorption on fecal short-chain fatty acid excretion in man. Scand. J. Gastroenterol. 23, 755-759.
105. Shoemaker, N. B., Wang, G.-R., and Salyers, A. A. (1992). Evidence for natural transfer of a tetracycline resistance gene between bacteria from the human colon and bacteria from the bovine rumen. Appl. Environ. Microbiol. 58, 1313-1320.
106. Shu, Y.-Z., Kingston, D. G. I., VanTassell, R. L. L., and Wilkins, T. D. (1991). Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica 21, 737-750.
107. th General Meeting American Society for Microbiology, p. 121.
108. Standiford, H. C., Walsh, T. J., Drusano, G. L., Tatem, B. A., and Townsend, R. J. (1993). Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination. Diagn. Microbiol. Infect. Dis. 17, 135-142.
109. Stephen, A. M., Wiggins, H. S., and Cummings, J. H. (1987). Effect of changing transit time on colonic microbial metabolism in man. Gut 28, 601-609.
110. Sutter, V. L., and Finegold, S. M. (1976). Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob. Agents Chemother. 10, 736-752.
111. Tancrede, C. (1992). Role of human microflora in health and disease. Eur. J. Clin. Microbiol. Infect. Dis. 11, 1012-1015.
112. Tancrede, C., and Barakat, R. (1989). Ecological impact of low doses of oxytetracycline on human intestinal microflora. J. Vet. Med. 42, 35-39.
113. Tannock, G. W. (1995). Normal Microflora: An Introduction to Microbes Inhabiting the Human Body, pp. 1-115. Chapman & Hall, London.
114. Taylor, R. M., Miller, W. L., and Vander Brook, M. J. (1956). Streptonivicin, a new antibiotic V. Absorption, distribution and excretion. Antibiotics Chemother. 6, 162-170.
115. Tedesco, F. J., Barton, R. W., and Alpers, D. H. (1974). Clindamycin-associated colitis. Ann. Int. Med. 81, 429-433.
116. Threlfall, E. J., Rowe, B., and Ward, L. R. (1993). A comparison of multiple drug resistance in Salmonella from humans and food animals in England and Wales, 1981 and 1990. Epidemiol. Infect. 111, 189-197.
117. Threlfall, E. J., Ward, L. R., Skinner, J. A., and Rowe, B. (1997). Increase in multiple antibiotic resistance in nontyphoidal salmonellas from humans in England and Wales: A comparison of data for 1994 and 1996. Microb. Drug Resist. 3, 263-266.
118. U.S. Food and Drug Administration (1993). Proposed Guideline: Microbiological Testing of Antimicrobial Drug Residues in Food. FDA, Rockville, MD. [December 2-16]
119. U.S. Food and Drug Administration (1996). Guidance: Microbiological Testing of Antimicrobial Drug Residues in Food. FDA, Rockville, MD.
120. Van der Waaij, L. A, Messerschmidt, O., and Van der Waaij, D. (1989). A norfloxacin dose finding study for selective decontamination of the digestive tract in pigs. Epidem. Inf. 102, 93-103.
121. van Saene, J. J., van Saene, H. K., Stoutenbeek, C. P., and Lerk, C. F. (1985). Influence of faeces on the activity of antimicrobial agents used for decontamination of the alimentary canal. Scand. J. Infect. Dis. 17, 295-300.
122. Veringa, E. M., and van der Waaij, D. (1984). Biological inactivation by faeces of antimicrobial drugs applicable in selective decontamination of the digestive tract. J. Antimicrob. Chemother. 14, 605-612.
123. Vollard, E. J., and Clasener, H. A. L. (1994). Colonization resistance. Antimicrob. Agents Chemother. 38, 409-414.
124. Wagman, G. H., Bailey, J. V., and Weinstein, M. J. (1974). Binding of aminoglycosides to feces. Antimicrob. Agents Chemother. 6, 415-417.
125. Wang, R.-F., Cao, W.-W., and Cerniglia, C. E. (1996). PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Appl. Environ. Microbiol. 62, 1242-1247.
126. Watanabe, Y., Hayashi, T., Kitayama, R., Yasuda, T., Saikawa, I., and Kihachiro, S. (1981). Studies on protein binding of antibiotics. III. Effect of novobiocin on protein binding and pharmacokinetics of cefoperazone and cefazolin. J. Antibiot. 34, 761-762.
127. Welch, H., Lewis, C. N., Putnam, L. E., and Randall, W. A. (1956). A study of the sensitizing potential of novobiocin. Antibiotic Med. Clin. Ther. 111, 27-32.
128. Wexler, H. M. (1991). Susceptibility testing of anaerobic bacteria: Myth, magic, or method? Clin. Infect. Dis. 4, 470-484.
129. Wexler, H. M. (1993). Susceptibility testing of anaerobic bacteria: The state of the art. Clin. Infect. Dis. 4, s328-s333.
130. Wong, W. C., Hentges, D. J., and Dougherty, S. H. (1996). Adequacy of the human fecal microbiota associated mouse as a model for studying the ecology of the human intestinal tract. Microb. Ecol. Health Dis. 9, 187-198.
131. Woodward, K. N. (1998). The use of microbiological end-points in the safety evaluation and elaboration of maximum residue limits for veterinary drugs intended for use in food producing animals. J. Vet. Pharmacol. Ther. 21, 47-53.